article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.

article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

The top 4 disease states this quarter were schizophrenia (41.7%), major depressive disorder (25%), and treatment-resistant depression (16.7%), and suicidal depression (16.7%). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

link] Newsletter Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients. Subscribe Now!

article thumbnail

June in Review: Updates on the Psychiatric Treatment Pipeline

Psychiatric Times

NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway. Ecopipam has demonstrated long-term safety and efficacy in reducing tic severity in pediatric patients with Tourette syndrome, with no tachyphylaxis observed.

article thumbnail

The 2025 Summer Heatwave: Implications for Patients With Psychiatric Disorders

Psychiatric Times

She has also served as advisory board participant for Supernus Pharmaceuticals and Axsome Therapeutics. Ms Barbee is a physician associate at Southlake Psychiatry in Davidson, North Carolina. She serves on speaker bureaus for Neurocrine Biosciences, Axsome Therapeutics, and Alkermes.

article thumbnail

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

Psychiatric Times

Teva Pharmaceuticals; 2025. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78(8):1136-1147. Austedo/AustedoXR. Prescribing information. Prescribing information. Neurocrine Biosciences Inc; 2025. Keepers GA, Fochtmann LJ, Anzia JM, et al.

article thumbnail

Rexulti in Combination With Sertraline for PTSD: Upcoming FDA Advisory Committee Discussion

Psychiatric Times

Dzmitry/AdobeStock On Friday July 18, 2025, the US Food and Drug Administration (FDA) advisory committee will discuss the supplemental New Drug Application (sNDA) for brexpiprazole (Rexulti) tablets, submitted by Otsuka Pharmaceutical Company, for the treatment of adults with posttraumatic stress disorder (PTSD), in combination with sertraline.